Delivery Order SPE2DR25D7005-SPE2DR26F3EXW
- Not listed
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Moxifloxacin HCL 400 mg tablets in unit dose packs of 50, with a ceiling value of $1,188.33. This is a firm fixed price delivery order with an ultimate completion date of July 22, 2025, and represents a competitively awarded, non-set-aside contract. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken,...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Moxifloxacin HCl 400 mg tablets in unit dose packages of 50 units. This contract, valued at $6,900, utilizes firm fixed pricing with an ultimate completion date of August 11, 2025. The award was made on a competitive basis with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime...
- The Defense Logistics Agency awarded a delivery order valued at $1,500.48 to AmerisourceBergen Drug Corp for the supply of Moxifloxacin HCL 400 mg tablets (30-count units). This competitively awarded, firm fixed-price delivery order was issued on July 18, 2025, with an ultimate completion date of July 21, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract contains no set-aside designation, indicating open competition among...
- The Defense Logistics Agency awarded a $4,902.80 delivery order to AmerisourceBergen Drug Corp for the supply of Moxifloxacin HCL 400 mg tablets (30-count units) on December 1, 2025, with completion scheduled for December 2, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Moxifloxacin HCL 400 mg tablets in unit dose packaging of 50 units. This competitively awarded, non-set-aside contract has a firm fixed price ceiling value of $2,572.99 with an ultimate completion date of August 7, 2025. The contract will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for moxifloxacin HCl 400 mg tablets (unit dose, 50s) with a ceiling value of $1,380.00. This competitive, non-set-aside contract was awarded on July 31, 2025, with a completion date of August 1, 2025. The order will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, under firm fixed-price terms as a delivery order, indicating this is a fulfillment against an...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Moxifloxacin HCL 400 mg tablets (30-count packages) with a contract ceiling value of $1,188.24. This competitively awarded, non-set-aside delivery order carries a firm fixed price and is scheduled for completion by September 15, 2025. The work will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Moxifloxacin HCl 400 mg tablets (30-count packaging) with a ceiling value of $1,596.49. This firm fixed-price delivery order is set to be completed by August 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract was awarded without set-aside designation through competitive...
- The Defense Logistics Agency (DLA) awarded a $3,530.37 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Moxifloxacin HCL 400 mg tablets in unit dose packaging of 50 tablets. The contract was competitively awarded without a set-aside designation and is scheduled for completion by January 29, 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Moxifloxacin HCL 400 mg tablets in unit dose packaging of 50s, with a ceiling value of $4,282.08 and completion deadline of August 15, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at the vendor's corporate headquarters in Conshohocken, Pennsylvania. The delivery order represents a tactical...
- SPE2DR25D7005Indefinite Delivery Contract
- SPE2DR25D7005-SPE2DR26F3EXWDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,516.25 to AmerisourceBergen Drug Corp for the supply of Moxifloxacin HCL 400 mg tablets in unit dose packaging of 50 units. This firm fixed-price contract, awarded on January 28, 2026, with an ultimate completion date of January 29, 2026, represents a routine pharmaceutical procurement supporting federal medical supply needs. The contract was competitively awarded with no set-aside designation and will be performed at the vendor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999.99 million through December 2031. This comprehensive IDC serves as the primary vehicle for supplying a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally, including medications across multiple therapeutic domains, vaccines, and specialized medical commodities. The award demonstrates the vendor's continued capability to efficiently fulfill government contracts for essential pharmaceutical products required by military treatment facilities and other federal medical institutions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 1/27/26 |